Literature DB >> 20666848

The evolving burden of HIV infection compared with other chronic diseases in northern Italy.

M Magoni1, C Scarcella, F Vassallo, F Lonati, G Carosi, F Castelnuovo, E Quiros-Roldan, L Albini, N Gennaro, D Bishai, A Tramarin, C Torti.   

Abstract

OBJECTIVES: The aim of the study was to estimate the burden and direct costs of diseases in HIV-infected patients (either opportunistic illnesses or other chronic diseases) with respect to the HIV-uninfected population. These estimates will be useful for the projection of future direct costs of HIV care. PATIENTS AND METHODS: A population-based study was conducted in the Brescia Local Health Agency in northern Italy. An administrative database recorded diagnoses, deaths, drug prescriptions and health resource utilization for all medical and surgical patients in the region from 2003 to 2007. The study estimated the prevalence of HIV infection as well as HIV-related mortality and annual cost per patient, and compared mortality and costs related to HIV infection with those for a set of 15 other chronic diseases. The standardized hazard ratio (SHR) and standardized mortality ratio (SMR) were obtained using an indirect standardization method.
RESULTS: The prevalence of HIV infection increased from 218 per 100,000 inhabitants in 2003 to 263 per 100,000 in 2007. Although mortality rates decreased markedly (from 24 per 1000 HIV-infected patients in 2003 to 16 per 1000 in 2007), the data show that mortality was still higher in HIV-infected patients compared with the general population in the most recent years (SMR 8.8 in 2007). In each year included in the study, HIV-infected patients had higher rates of care-seeking for chronic diseases, including liver diseases (SHR>8), neuropathy, oesophagus-gastro-duodenum diseases, serious psychiatric disorders and renal failure (SHR approximately 3 for each). Also, the rate of medical attendance for neoplasias, chronic pulmonary disease, diabetes, and cardiovascular disease increased over time in HIV-infected patients compared with the general population. Ranking diseases in order of their total cost to the health system, HIV infection ranked 12th, with total costs of €28.6 million in 2007. Ranking in order of cost per patient, HIV infection ranked third, with a cost per patient of €9894 in 2007. HIV-infected patients with concomitant chronic diseases had higher average costs. The cost per patient in 2007 was €8104 for HIV-infected patients without other chronic diseases, €9908 for HIV infection plus cardiovascular disease, €11,370 for HIV infection plus chronic liver disease and €12,013 for HIV infection plus neoplasias.
CONCLUSIONS: The prevalence and population cost of people living with HIV are likely to increase as a result of prolonged survival, aging of HIV-infected patients and increased risk of other chronic diseases. In the near future, HIV infection will rank as one of the most costly chronic diseases. Prevention strategies need to be more widely adopted to control the growing burden of the HIV epidemic and other chronic diseases affecting HIV-infected patients.
© 2010 British HIV Association.

Entities:  

Mesh:

Year:  2011        PMID: 20666848     DOI: 10.1111/j.1468-1293.2010.00861.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  10 in total

1.  Obesity is associated with race/sex disparities in diabetes and hypertension prevalence, but not cardiovascular disease, among HIV-infected adults.

Authors:  Amanda L Willig; Andrew O Westfall; E Turner Overton; Michael J Mugavero; Greer A Burkholder; David Kim; Eric Chamot; James L Raper; Heidi M Crane; Michael S Saag; James H Willig
Journal:  AIDS Res Hum Retroviruses       Date:  2015-07-23       Impact factor: 2.205

2.  Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile?

Authors:  Giuliano Rizzardini; Umberto Restelli; Paolo Bonfanti; Emanuele Porazzi; Elena Ricci; Emanuela Foglia; Laura Carenzi; Davide Croce
Journal:  Clinicoecon Outcomes Res       Date:  2012-09-05

3.  Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort.

Authors:  Monica Tontodonati; Giovanni Cenderello; Benedetto Maurizio Celesia; Michele Trezzi; Tamara Ursini; Andrea Costantini; Domenico Marra; Ennio Polilli; Corrado Catalani; Luca Butini; Federica Sozio; Elena Mazzotta; Antonina Sciacca; Giuliano Rizzardini; Lamberto Manzoli; Alessandro Cozzi-Lepri; Giustino Parruti
Journal:  Clinicoecon Outcomes Res       Date:  2014-12-22

4.  Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.

Authors:  Gilles Pialoux; Anne-Geneviève Marcelin; Nicolas Despiégel; Caroline Espinas; Hélène Cawston; Laurent Finkielsztejn; Audrey Laurisse; Céline Aubin
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

5.  Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study.

Authors:  Giovanni Guaraldi; Stefano Zona; Marianna Menozzi; Thomas D Brothers; Federica Carli; Chiara Stentarelli; Giovanni Dolci; Antonella Santoro; Ana Rita Domingues Da Silva; Elisa Rossi; Julian Falutz; Cristina Mussini
Journal:  AIDS Res Ther       Date:  2017-02-16       Impact factor: 2.250

Review 6.  Cost of noninfectious comorbidities in patients with HIV.

Authors:  Giovanni Guaraldi; Stefano Zona; Marianna Menozzi; Federica Carli; Pietro Bagni; Alessandra Berti; Elisa Rossi; Gabriella Orlando; Giuliana Zoboli; Frank Palella
Journal:  Clinicoecon Outcomes Res       Date:  2013-09-23

7.  New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy).

Authors:  Umberto Restelli; Francesca Scolari; Paolo Bonfanti; Davide Croce; Giuliano Rizzardini
Journal:  BMC Infect Dis       Date:  2015-08-11       Impact factor: 3.090

8.  The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population.

Authors:  Eugenia Quiros-Roldan; Michele Magoni; Elena Raffetti; Francesco Donato; Carmelo Scarcella; Giuseppe Paraninfo; Francesco Castelli
Journal:  BMC Public Health       Date:  2016-11-09       Impact factor: 3.295

9.  Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study.

Authors:  Mikaela Smit; Rachel Cassidy; Alessandro Cozzi-Lepri; Eugenia Quiros-Roldan; Enrico Girardi; Alessia Mammone; Andrea Antinori; Annalisa Saracino; Francesca Bai; Stefano Rusconi; Giacomo Magnani; Francesco Castelli; Priscilla Hsue; Antonella d'Arminio Monforte; Timothy B Hallett
Journal:  PLoS One       Date:  2017-10-23       Impact factor: 3.240

10.  How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy.

Authors:  Lucia Taramasso; Federica Demma; Rossella Bitonti; Antonio Ferrazin; Barbara Giannini; Mauro Giacomini; Sabrina Beltramini; Elisabetta Sasso; Claudio Viscoli; Antonio Di Biagio
Journal:  BMC Health Serv Res       Date:  2018-09-06       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.